Journal
JOURNAL OF CLINICAL MEDICINE
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/jcm12062378
Keywords
Waldenstrom; macroglobulinemia; BeEAM; high-dose chemotherapy; autologous stem cell transplantation
Categories
Ask authors/readers for more resources
In this pilot study, high-dose chemotherapy with BeEAM, using bendamustine as an alternative to BCNU, was well tolerated and effective in patients with Waldenstrom's macroglobulinemia (WM). All 6 patients achieved partial responses or very good partial responses. This conditioning regimen seems to be feasible and safe for WM patients undergoing autologous stem cell transplantation.
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom's macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM. Bendamustine treatment was well tolerated without unexpected toxicities. The overall response rate was 6/6 patients (2 very good partial responses (VGPR) and 4 PR). After a median follow-up of 72 months, two (33%) patients relapsed. Median progression-free and overall survivals were not reached, and no severe late-onset toxicities were observed so far. In this pilot study, BeEAM conditioning before ASCT seems feasible, safe, and effective in patients with WM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available